MedTrace Logo

Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism

NCT06164379 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-12-11

No results posted yet for this study

Summary

To study the efficacy and safety of finerenone vs. spironolactone in patients with primary aldosteronism

Conditions

  • Primary Aldosteronism

Interventions

DRUG

Finerenone

At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.

DRUG

Spironolactone

At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Jiguang Wang, MD. PhD · Department of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-16
Primary Completion
2024-12-16
Completion
2024-12-16

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06164379 on ClinicalTrials.gov